RESUMO
AIM: To study efficacy of complex therapy of urogenital infections caused by Chlamydia and Mycoplasma using immunomodulator Superlimph. MATERIALS AND METHODS: Fifty males and thirty six females ages 22 - 47 years old with chronic urogenital infections--cervicitis and vulvovaginitis (females), prostatitis (males)--were studied. PCR and bacteriologic methods were used for diagnostics of mixed infection and microbiota efficiency. Patients were divided on 3 groups according to treatment protocol. Twenty patients (group 1)--standard therapy (josamycin), 48 patients received immunomodulator (suppositorium) before treatment with josamycin (group 2), 18 patients were simultaneously treated with josamycin and immunomodulator (group 3). RESULTS: Combinations of Chlamydia trachomatis, Ureaplasma urealyticum, Gardnerella vaginalis and Mycoplasma genitalium were identified in 30 - 35% of cases before treatment. After treatment with josamycin (group 1) or simultaneous therapy with josamycin and immunomodulator (group 3) considerable suppression of growth and elimination of both main pathogens and members of microbiota. Use of immunomodulator (group 2) in some cases resulted elimination of main pathogens and associated opportunistic microflora. CONCLUSION: Microbiological monitoring in 97% cases demonstrated therapeutic effect of immunomodulator Superlymph on urogenital infections associated with Chlamydia and Mycoplasma and disbiotic microbiota of urogenital tract.
